A metabolic treatment for pancreatic cancer?

August 15, 2017, Children's Hospital Boston
Axial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domain

Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research led by Nada Kalaany, PhD, at Boston Children's Hospital and the Broad Institute of MIT and Harvard, now suggests a novel approach to treating this deadly cancer: targeting an enzyme that tumors use to get rid of nitrogen.

The study, published online today in Nature Communications, provides evidence that targeting the enzyme arginase 2 (ARG2) can curb the growth of pancreatic tumors, especially in people who are obese.

The researchers began by introducing human pancreatic tumors into obese and lean mice. They then analyzed what genes the tumors turned on and what metabolic products they were producing. They found that tumors in obese mice had enhanced expression of many genes involved in metabolizing , a natural byproduct of cells when proteins are broken down.

Until now, how nitrogen excess affects growth has been largely unknown.

"We found that highly malignant pancreatic tumors are very dependent on the nitrogen metabolism pathway," says Kalaany, a researcher in Boston Children's Division of Endocrinology and an assistant professor at Harvard Medical School.

Curbing tumor growth by preventing nitrogen disposal

Pancreatic tumors grew faster in obese mice than in lean mice and produced increased amounts of ARG2, an enzyme that helps dispose of excess nitrogen by breaking down ammonia, as part of the urea cycle.

Kalaany and colleagues also analyzed tumor samples removed from 92 patients with pancreatic , through collaboration with Massachusetts General Hospital and the Dana-Farber Cancer Institute. They showed that ARG2 levels in the tumors increased together with patients' body mass index (BMI).

When the researchers silenced or deleted ARG2 in the tumors of obese mice, nitrogen accumulated (in the form of ammonia) and cancer growth was strongly suppressed.

"Pancreatic tumors are known to take up and break down large amounts of protein to fuel their growth," explains Kalaany. "They need ARG2 to get rid of the extra nitrogen and prevent ammonia from accumulating."

Not just the obese

Although grew more robustly in the obese mice and produced more ARG2, as did tumors from higher-BMI patients, tumors in lean mice appear to activate the same metabolic pathway.

"In a lean mouse model bearing fast-growing tumors, we saw the same transcriptomic signature that we did in the ," says Kalaany. "It seems obesity or rapid growth exaggerate a tumor's need to get rid of nitrogen."

ARG2 is closely related to ARG1, the liver enzyme we ourselves use to rid our bodies of . In mouse models and in humans, deficiencies of ARG1 have been shown to cause neurological impairment, growth retardation and fatal ammonia toxicity. But deleting the ARG2 gene does not appear to cause serious side effects, at least in .

"There could be a therapeutic window here," says Kalaany. The team plans to conduct chemical screens to identify inhibitors of arginase 2 that could potentially be used as drugs. Most known inhibitors also inhibit arginase 1, but at least one has action more specific to arginase 2, she says.

"Pancreatic cancer is notoriously resistant to conventional treatment options," said Julie Fleshman, JD, MBA, president and CEO at the Pancreatic Cancer Action Network, which helped fund this work. "The discovery of novel drug targets like ARG2 could have a significant impact on patient outcomes and move us closer to our goal to double survival by 2020."

Explore further: Study pinpoints gene's role in pancreatic cancer

Related Stories

Study pinpoints gene's role in pancreatic cancer

August 11, 2017
Pancreatic cancer is a particularly deadly form of disease, and patients have few options for effective treatment. But a new Yale-led study has identified a gene that is critical to pancreatic cancer cell growth, revealing ...

Researchers find novel way to induce pancreatic cancer cell death

April 10, 2017
Pancreatic cancer, most frequently pancreatic ductal adenocarcinoma (PDAC), is the most lethal and aggressive of all cancers. Unfortunately, there are not many effective therapies available other than surgery, and that is ...

Study reaffirms the belief that malignant cell behavior is influenced by the tumor tissue of origin

September 9, 2016
(Medical Xpress)—A team of researchers affiliated with several institutions in the U.S. has conducted a study of cancer in mice and found evidence that reaffirms results from prior research suggesting that malignant cell ...

Starving pancreatic cancer cells: Scientists identify potential pancreatic cancer target

October 17, 2016
Researchers have found that a protein called SLC6A14 is overexpressed by several fold in pancreatic tumors taken from patients and in cancerous pancreatic cells lines compared with normal pancreatic tissue or normal pancreatic ...

Scientists find potential loophole in pancreatic cancer defenses

March 27, 2013
Dana-Farber Cancer Institute scientists and colleagues have discovered that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control ...

Recommended for you

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

Method identified to reduce risk of brain damage in leukemia survivors

September 25, 2018
Children with acute lymphoblastic leukemia (ALL) are at an extremely high risk of sepsis compared to the general population. In the first-published study of its kind, St. Jude Children's Research Hospital scientists have ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.